Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

PFSA US Equity

Profusa, Inc.Health Care · Surgical & Medical Instruments & Apparatus · CIK 1859807 · FY ends Dec 31
$27.48
+22.95 (+506.62%)
USD · as of 2026-08-18 · marketstack
1 registered study · 1 active

Studies where PFSA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional

Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionReadout inUpdated
Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2NCT04514861Correlation of subcutaneous oxygen dynamics measured by the Wireless Lumee Oxygen Platform and a TcPO2 device in the armOpen-label · Basic scienceNot applicableActive, not recruitingDevice: Wireless Lumee Oxygen PlatformPeripheral Artery Disease532027-03-30in 223 d2025-11-12

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19